Akamis Bio Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 34

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $60M

  • Investors
  • 25

Akamis Bio General Information

Description

Operator of a clinical-stage oncology company intended to develop cancer gene therapies. The company focuses on immunobiology treatments for solid tumors using the proprietary intravenously administered T-SIGn virus platform, enabling patients to get proper treatment who are suffering from cancer.

Contact Information

Formerly Known As
PsiOxus Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4-10 The Quadrant, Abingdon Science Park
  • Barton Lane, Oxfordshire
  • Abingdon OX14 3YS
  • England, United Kingdom
+44 01235
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 4-10 The Quadrant, Abingdon Science Park
  • Barton Lane, Oxfordshire
  • Abingdon OX14 3YS
  • England, United Kingdom
+44 01235

Akamis Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Akamis Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC (Series A) 17-Dec-2024 $60M Completed Clinical Trials - Phase 1
13. Later Stage VC 05-Jan-2023 Completed Clinical Trials - Phase 1
12. Secondary Transaction - Private 27-Jan-2021 Completed Pre-Clinical Trials
11. Later Stage VC 16-Sep-2019 Completed Pre-Clinical Trials
10. Later Stage VC (Series C) 19-May-2015 Completed Pre-Clinical Trials
9. Grant 07-Oct-2013 Completed Pre-Clinical Trials
8. Grant 31-Oct-2012 Completed Pre-Clinical Trials
7. Later Stage VC (Series B) 16-Oct-2012 Completed Pre-Clinical Trials
6. Grant 12-Sep-2011 $2.92M $10.3M Completed Pre-Clinical Trials
5. Early Stage VC 15-Dec-2010 $5.68M $10.3M Completed Pre-Clinical Trials
To view Akamis Bio’s complete valuation and funding history, request access »

Akamis Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B-2 Preferred
Series B
Series B
Series B
Series B
Series B
Series B
Series A 981 $0.012138 $53.41 $53.41 1x $53.41 0.06%
Series A 126,176 $0.012138 $66.76 $66.76 1x $66.76 7.79%
To view Akamis Bio’s complete cap table history, request access »

Akamis Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage oncology company intended to develop cancer gene therapies. The company focuses on immunobi
Drug Discovery
Abingdon, United Kingdom
34 As of 2025

Woburn, MA
 

Hampton, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Akamis Bio Competitors (55)

One of Akamis Bio’s 55 competitors is Replimune, a Formerly VC-backed company based in Woburn, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Replimune Formerly VC-backed Woburn, MA
Celldex Formerly VC-backed Hampton, NJ
Oncorus Formerly VC-backed Andover, MA
Rein Therapeutics Formerly VC-backed Austin, TX
Macrogenics Formerly VC-backed Rockville, MD
You’re viewing 5 of 55 competitors. Get the full list »

Akamis Bio Patents

Akamis Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026117753-A1 Viral vectors for expression of synthetic cancer antigens and chemokine and related methods and uses Pending 27-Nov-2024
AU-2025220163-A1 Engineered cancer antigens and related methods and uses Pending 09-Feb-2024
WO-2025171383-A2 Engineered cancer antigens and related methods and uses Pending 09-Feb-2024
WO-2025171383-A3 Engineered cancer antigens and related methods and uses Pending 09-Feb-2024
GB-202211075-D0 Virus Inactive 28-Jul-2022
To view Akamis Bio’s complete patent history, request access »

Akamis Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Akamis Bio Investors (25)

Investor Name Investor Type Holding Investor Since Participating Rounds
Lundbeckfonden Limited Partner Minority
Parker Institute for Cancer Immunotherapy Corporation
Westlake Village BioPartners Venture Capital Minority
Bristol-Myers Squibb Corporation Minority
Rosetta Capital (UK) Venture Capital Minority
You’re viewing 5 of 25 investors. Get the full list »

Akamis Bio FAQs

  • When was Akamis Bio founded?

    Akamis Bio was founded in 2006.

  • Where is Akamis Bio headquartered?

    Akamis Bio is headquartered in Abingdon, United Kingdom.

  • What is the size of Akamis Bio?

    Akamis Bio has 34 total employees.

  • What industry is Akamis Bio in?

    Akamis Bio’s primary industry is Drug Discovery.

  • Is Akamis Bio a private or public company?

    Akamis Bio is a Private company.

  • What is Akamis Bio’s current revenue?

    The current revenue for Akamis Bio is .

  • How much funding has Akamis Bio raised over time?

    Akamis Bio has raised $185M.

  • Who are Akamis Bio’s investors?

    Lundbeckfonden, Parker Institute for Cancer Immunotherapy, Westlake Village BioPartners, Bristol-Myers Squibb, and Rosetta Capital (UK) are 5 of 25 investors who have invested in Akamis Bio.

  • Who are Akamis Bio’s competitors?

    Replimune, Celldex, Oncorus, Rein Therapeutics, and Macrogenics are some of the 55 competitors of Akamis Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process